SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lakatos Peter L.)
 

Sökning: WFRF:(Lakatos Peter L.) > (2020-2023) > The Future of Biosi...

  • Kim, HoUngCelltrion Healthcare, Incheon, Republic of Korea; Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea (författare)

The Future of Biosimilars : Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020-01-30
  • Adis International,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-79882
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-79882URI
  • https://doi.org/10.1007/s40265-020-01256-5DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agency:Celltrion Healthcare Co., Ltd
  • Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Alten, RiekeDepartment of Internal Medicine and Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany (författare)
  • Avedano, LuisaEuropean Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium (författare)
  • Dignass, AxelDepartment of Medicine 1, Agaplesion Markus Hospital, Frankfurt am Main, Germany (författare)
  • Gomollon, FernandoGastroenterology Unit, Clinical University Hospital Lozano Bless IIS Aragón, Zaragoza, Spain (författare)
  • Greveson, KayCentre for Gastroenterology, Royal Free Hospital, London, UK (författare)
  • Halfvarson, Jonas,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology(Swepub:oru)jshn (författare)
  • Irving, Peter M.IBD Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK (författare)
  • Jahnsen, JørgenDepartment of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway (författare)
  • Lakatos, Peter L.Division of Gastroenterology, McGill University, Montreal QC, Canada; 1st Department of Medicine, Semmelweis University, Budapest, Hungary (författare)
  • Lee, JongHyukDepartment of Pharmaceutical Engineering, College of Life and Health Science, Hoseo University, Asan, Republic of Korea (författare)
  • Makri, SouziCyprus League Against Rheumatism, Nicosia, Cyprus (författare)
  • Parker, BenKellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK (författare)
  • Peyrin-Biroulet, LaurentInflammatory Bowel Disease Unit, Nancy University Hospital, Allée du Morvan, France (författare)
  • Schreiber, StefanDepartment Medicine I, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany (författare)
  • Simoens, StevenDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium (författare)
  • Westhovens, ReneDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Rheumatology University Hospital Leuven, Leuven, Belgium (författare)
  • Danese, SilvioDepartment of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy (författare)
  • Jeong, Ji HoonDepartment of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea (författare)
  • Celltrion Healthcare, Incheon, Republic of Korea; Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of KoreaDepartment of Internal Medicine and Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Drugs: Adis International80:2, s. 99-1130012-66671179-1950

Internetlänk

Hitta via bibliotek

  • Drugs (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy